Supplementary Figure 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
<p>Overall survival of ATM, BRCA2 mutant, and HRDother mPCs.</p>
Gorde:
Antzeko izenburuak
-
Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
nork: Justin Hwang (15925675)
Argitaratua: (2025) -
Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
nork: Justin Hwang (15925675)
Argitaratua: (2025) -
Supplementary Table 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
nork: Justin Hwang (15925675)
Argitaratua: (2025) -
Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
nork: Justin Hwang (15925675)
Argitaratua: (2025) -
Supplementary Table 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
nork: Justin Hwang (15925675)
Argitaratua: (2025)